 Quality-Adjusted Life Years
"Quality-Adjusted Life Years" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A measurement index derived from a modification of standard life-table procedures and designed to take account of the quality as well as the duration of survival. This index can be used in assessing the outcome of health care procedures or services. (BIOETHICS Thesaurus, 1994)
| Descriptor ID |
D019057
|
| MeSH Number(s) |
E05.318.740.100.500.700 N01.224.935.530.700
|
| Concept/Terms |
Quality-Adjusted Life Years- Quality-Adjusted Life Years
- Life Year, Quality-Adjusted
- Life Years, Quality-Adjusted
- Quality-Adjusted Life Year
- Year, Quality-Adjusted Life
- Years, Quality-Adjusted Life
- Quality Adjusted Life Years
- QALY
Adjusted Life Years- Adjusted Life Years
- Adjusted Life Year
- Life Year, Adjusted
- Life Years, Adjusted
- Year, Adjusted Life
- Years, Adjusted Life
|
Below are MeSH descriptors whose meaning is more general than "Quality-Adjusted Life Years".
Below are MeSH descriptors whose meaning is more specific than "Quality-Adjusted Life Years".
This graph shows the total number of publications written about "Quality-Adjusted Life Years" by people in this website by year, and whether "Quality-Adjusted Life Years" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 2 | 2 | | 2000 | 1 | 2 | 3 | | 2001 | 0 | 1 | 1 | | 2005 | 0 | 2 | 2 | | 2006 | 1 | 1 | 2 | | 2007 | 0 | 2 | 2 | | 2009 | 0 | 3 | 3 | | 2010 | 1 | 1 | 2 | | 2011 | 0 | 3 | 3 | | 2012 | 1 | 3 | 4 | | 2013 | 2 | 3 | 5 | | 2014 | 0 | 6 | 6 | | 2015 | 0 | 3 | 3 | | 2016 | 0 | 4 | 4 | | 2017 | 0 | 3 | 3 | | 2018 | 0 | 5 | 5 | | 2019 | 2 | 8 | 10 | | 2020 | 1 | 7 | 8 | | 2021 | 0 | 5 | 5 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 2 | 2 | | 2024 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Quality-Adjusted Life Years" by people in Profiles.
-
DiStefano MJ, Zemplenyi A, Anderson KE, Mendola ND, Nair KV, McQueen RB. Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare drug price negotiation program. Expert Rev Pharmacoecon Outcomes Res. 2024 Feb; 24(2):171-180.
-
Ren K, Liu C, He Z, Wu P, Zhang J, Yang R, Cui T, Song K, Cheng D, He K, Yu J. Pancreatic Cancer and its Attributable Risk Factors in East Asia, Now and Future. Oncologist. 2023 Nov 02; 28(11):e995-e1004.
-
Biskupiak JE, Ramos M, Levy CJ, Forlenza G, Hopley C, Boyd J, Swift D, Lamotte M, Brixner DI. Cost-effectiveness of the tubeless automated insulin delivery system vs standard of care in the management of type 1 diabetes in the United States. J Manag Care Spec Pharm. 2023 Jul; 29(7):807-817.
-
McQueen RB, Anderson KE, Levy JF, Carlson JJ. Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable? Pharmacoeconomics. 2023 03; 41(3):321-327.
-
Kim N, Wang J, Burudpakdee C, Song Y, Ramasamy A, Xie Y, Sun R, Kumar N, Wu EQ, Sullivan SD. Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States. J Manag Care Spec Pharm. 2022 Jul; 28(7):740-752.
-
Wang L, Scott FI, Boursi B, Reiss KA, Williams S, Glick H, Yang YX. Cost-Effectiveness of a Risk-Tailored Pancreatic Cancer Early Detection Strategy Among Patients With New-Onset Diabetes. Clin Gastroenterol Hepatol. 2022 09; 20(9):1997-2004.e7.
-
Greenhawt M, Oppenheimer J, Codispoti CD. A Practical Guide to Understanding Cost-Effectiveness Analyses. J Allergy Clin Immunol Pract. 2021 12; 9(12):4200-4207.
-
Ma X, Zhu L, Kurche JS, Xiao H, Dai H, Wang C. Global and regional burden of interstitial lung disease and pulmonary sarcoidosis from 1990 to 2019: results from the Global Burden of Disease study 2019. Thorax. 2022 06; 77(6):596-605.
-
Launer BM, Lloyd GL. Sociodemographic index and global trends in prostate cancer: 1990-2017. Prostate. 2021 09; 81(12):825-831.
-
Smare C, Dave K, Juarez-Garcia A, Abraham P, Penrod JR, Camidge DR, Yuan Y. Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer. J Med Econ. 2021 Jan-Dec; 24(1):1124-1133.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|